Communiqués EyePoint, Inc.

Actions

EYPT

US30233G2093

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 01/10/2026			Varia. 5j.	Varia. 1 janv.
3,230 ^USD	-1,22%		-11,51%	-82,32%

15/09	Transcript : EyePoint, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM
09/09	Transcript : EyePoint, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM

Communiqués

16/09	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
02/09	EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting	AQ
18/08	EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU 2.7mg in Wet AMD	AQ
17/08	EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD	AQ
17/08	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
14/08	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
05/08	EyePoint: Q2 Earnings Snapshot	AQ
05/08	EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments	AQ
30/07	EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)	AQ
16/07	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
13/07	EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer	AQ
16/06	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
19/05	EyePoint Announces Participation at Upcoming Investor Conferences	AQ
18/05	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
14/05	EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data	AQ
06/05	EyePoint: Q1 Earnings Snapshot	AQ
06/05	EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments	AQ
29/04	EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026	AQ
16/04	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
16/03	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	AQ
04/03	EyePoint: Q4 Earnings Snapshot	AQ
04/03	EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments	AQ
02/03	EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema	AQ
25/02	EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026	AQ
24/02	EyePoint Announces Participation at Upcoming Investor Conferences	AQ